Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA)‘s stock had its “neutral” rating reiterated by Goldman Sachs Group, Inc. (The) in a research report issued on Thursday, The Fly reports. They currently have a $14.00 target price on the biotechnology company’s stock, down from their previous target price of $18.00. Goldman Sachs Group, Inc. (The)’s price objective would indicate a potential downside of 7.28% from the company’s current price.

Several other research firms have also weighed in on MNTA. Stifel Nicolaus reiterated a “buy” rating and set a $26.00 target price on shares of Momenta Pharmaceuticals in a research note on Thursday, August 3rd. Barclays PLC lowered their target price on shares of Momenta Pharmaceuticals from $17.00 to $16.00 and set an “equal weight” rating for the company in a research note on Wednesday. BidaskClub lowered shares of Momenta Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, July 6th. Zacks Investment Research upgraded shares of Momenta Pharmaceuticals from a “hold” rating to a “buy” rating and set a $20.00 target price for the company in a research note on Wednesday. Finally, Maxim Group set a $6.00 target price on shares of Momenta Pharmaceuticals and gave the company a “sell” rating in a research note on Thursday, August 3rd. Two research analysts have rated the stock with a sell rating, six have assigned a hold rating and two have issued a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average target price of $15.44.

Shares of Momenta Pharmaceuticals (NASDAQ MNTA) opened at 15.10 on Thursday. The firm’s market cap is $1.12 billion. Momenta Pharmaceuticals has a 1-year low of $10.75 and a 1-year high of $19.90. The stock has a 50 day moving average of $16.83 and a 200 day moving average of $15.81.

Momenta Pharmaceuticals (NASDAQ:MNTA) last released its earnings results on Wednesday, August 2nd. The biotechnology company reported ($0.50) earnings per share for the quarter, meeting the consensus estimate of ($0.50). Momenta Pharmaceuticals had a negative net margin of 39.35% and a negative return on equity of 12.28%. The firm had revenue of $23.57 million during the quarter, compared to analyst estimates of $24.64 million. During the same quarter in the previous year, the firm earned ($0.31) earnings per share. The firm’s revenue for the quarter was down 10.8% compared to the same quarter last year. Equities research analysts anticipate that Momenta Pharmaceuticals will post ($1.53) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This news story was first published by American Banking News and is the property of of American Banking News. If you are reading this news story on another website, it was illegally stolen and reposted in violation of United States & international trademark and copyright law. The legal version of this news story can be viewed at https://www.americanbankingnews.com/2017/10/05/goldman-sachs-group-inc-the-reaffirms-neutral-rating-for-momenta-pharmaceuticals-inc-mnta.html.

In other news, President Craig A. Wheeler sold 4,116 shares of the company’s stock in a transaction dated Monday, August 21st. The shares were sold at an average price of $15.07, for a total transaction of $62,028.12. Following the completion of the transaction, the president now owns 269,231 shares in the company, valued at $4,057,311.17. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, President Craig A. Wheeler sold 35,667 shares of the company’s stock in a transaction dated Thursday, September 28th. The stock was sold at an average price of $19.03, for a total transaction of $678,743.01. Following the transaction, the president now owns 286,121 shares of the company’s stock, valued at approximately $5,444,882.63. The disclosure for this sale can be found here. Insiders have sold 79,663 shares of company stock valued at $1,414,498 in the last 90 days. Insiders own 4.40% of the company’s stock.

Institutional investors and hedge funds have recently made changes to their positions in the stock. Edmond DE Rothschild Holding S.A. bought a new position in Momenta Pharmaceuticals in the 1st quarter valued at about $5,607,000. Great West Life Assurance Co. Can grew its position in Momenta Pharmaceuticals by 8.4% in the 2nd quarter. Great West Life Assurance Co. Can now owns 96,471 shares of the biotechnology company’s stock valued at $1,625,000 after buying an additional 7,450 shares in the last quarter. Rhumbline Advisers grew its position in Momenta Pharmaceuticals by 8.6% in the 2nd quarter. Rhumbline Advisers now owns 140,215 shares of the biotechnology company’s stock valued at $2,370,000 after buying an additional 11,128 shares in the last quarter. Comerica Bank grew its position in Momenta Pharmaceuticals by 5.4% in the 1st quarter. Comerica Bank now owns 71,875 shares of the biotechnology company’s stock valued at $1,006,000 after buying an additional 3,652 shares in the last quarter. Finally, JPMorgan Chase & Co. grew its position in Momenta Pharmaceuticals by 65.1% in the 1st quarter. JPMorgan Chase & Co. now owns 636,744 shares of the biotechnology company’s stock valued at $8,500,000 after buying an additional 251,159 shares in the last quarter. Hedge funds and other institutional investors own 93.86% of the company’s stock.

About Momenta Pharmaceuticals

Momenta Pharmaceuticals, Inc is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. The Company has developed generic version of LOVENOX (enoxaparin sodium injection) and COPAXONE (glatiramer acetate injection).

The Fly

Analyst Recommendations for Momenta Pharmaceuticals (NASDAQ:MNTA)

Receive News & Ratings for Momenta Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.